EA201170942A1 - СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ - Google Patents

СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ

Info

Publication number
EA201170942A1
EA201170942A1 EA201170942A EA201170942A EA201170942A1 EA 201170942 A1 EA201170942 A1 EA 201170942A1 EA 201170942 A EA201170942 A EA 201170942A EA 201170942 A EA201170942 A EA 201170942A EA 201170942 A1 EA201170942 A1 EA 201170942A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rhc
activators
treatment
combination
dysfunction
Prior art date
Application number
EA201170942A
Other languages
English (en)
Inventor
Петер Занднер
Йоханнес-Петер Сташ
Михаель-Фридрих Бёттхер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201170942A1 publication Critical patent/EA201170942A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Данное изобретение касается растворимой гуанилатциклазы (рГЦ) и фосфодистеразы (ФДЭ) и фармакологии стимуляторов рГЦ, активаторов рГЦ и ингибиторов ФДЭ. В частности, изобретение касается применения стимуляторов рГЦ и активаторов рГЦ в комбинации с ингибиторами ФДЭ5 для приготовления лекарственных препаратов для лечения мужской эректильной дисфункции (МЭД), в частности для лечения МЭД у тяжелых пациентов, и тех, которые не отвечают или не полностью отвечают на ингибиторы ФДЭ5.
EA201170942A 2009-01-17 2010-01-07 СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ EA201170942A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09000619 2009-01-17
EP09002177 2009-02-17
PCT/EP2010/000029 WO2010081647A2 (en) 2009-01-17 2010-01-07 Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
EA201170942A1 true EA201170942A1 (ru) 2012-02-28

Family

ID=42153923

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170942A EA201170942A1 (ru) 2009-01-17 2010-01-07 СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ

Country Status (20)

Country Link
US (2) US20120022028A1 (ru)
EP (1) EP2387404B1 (ru)
JP (1) JP5780430B2 (ru)
KR (1) KR20110117655A (ru)
CN (1) CN102316870A (ru)
AU (1) AU2010205931A1 (ru)
BR (1) BRPI1006869A2 (ru)
CA (1) CA2749730C (ru)
CL (1) CL2011001712A1 (ru)
EA (1) EA201170942A1 (ru)
ES (1) ES2493718T3 (ru)
IL (1) IL213857A0 (ru)
MA (1) MA32967B1 (ru)
MX (1) MX2011007515A (ru)
SG (1) SG172841A1 (ru)
SV (1) SV2011003973A (ru)
TN (1) TN2011000349A1 (ru)
TW (1) TW201036971A (ru)
WO (1) WO2010081647A2 (ru)
ZA (1) ZA201105085B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095553A1 (en) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
NZ603799A (en) 2010-05-26 2014-10-31 Bayer Ip Gmbh The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
EP2585055A1 (de) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
WO2012122340A1 (en) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US8815857B2 (en) 2011-08-12 2014-08-26 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
KR101960100B1 (ko) * 2011-12-08 2019-03-19 에스케이케미칼 주식회사 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름
GEP20176631B (en) * 2012-09-07 2017-02-27 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
TWI711615B (zh) 2014-07-22 2020-12-01 德商百靈佳殷格翰國際股份有限公司 作為可溶性鳥苷酸環化酶活化劑的雜環羧酸
DK3377495T3 (da) 2015-11-16 2022-05-09 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf
AU2018274599B9 (en) 2017-05-22 2022-04-07 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
CN110305837A (zh) * 2019-06-05 2019-10-08 西北师范大学 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB369003A (en) 1931-03-25 1932-03-17 Richard Henry Sansome Improvements in fire extinguishing fluids
CZ302691B6 (cs) * 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
RU2009145935A (ru) * 2007-05-12 2011-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений

Also Published As

Publication number Publication date
AU2010205931A1 (en) 2011-07-28
WO2010081647A2 (en) 2010-07-22
ZA201105085B (en) 2012-09-26
EP2387404A2 (en) 2011-11-23
US20120022028A1 (en) 2012-01-26
TN2011000349A1 (en) 2013-03-27
JP2012515176A (ja) 2012-07-05
MA32967B1 (fr) 2012-01-02
MX2011007515A (es) 2011-08-12
EP2387404B1 (en) 2014-06-25
TW201036971A (en) 2010-10-16
CA2749730A1 (en) 2010-07-22
BRPI1006869A2 (pt) 2016-03-15
CN102316870A (zh) 2012-01-11
WO2010081647A3 (en) 2010-10-21
SV2011003973A (es) 2011-12-06
CL2011001712A1 (es) 2012-04-09
CA2749730C (en) 2017-02-14
US20140288079A1 (en) 2014-09-25
KR20110117655A (ko) 2011-10-27
IL213857A0 (en) 2011-07-31
ES2493718T3 (es) 2014-09-12
JP5780430B2 (ja) 2015-09-16
SG172841A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
EA201170942A1 (ru) СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
EA201290702A1 (ru) СТИМУЛЯТОРЫ sGC ИЛИ АКТИВАТОРЫ sGC, ПРИМЕНЯЕМЫЕ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРАМИ PDE5
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MX2019007080A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX2016012365A (es) Combinaciones.
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
UA105911C2 (ru) Сульфонамидные производные
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
GB201104267D0 (en) Pyrrolopyridineamino derivatives
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EA201270264A1 (ru) Лечение метастазов в головной мозг ингибиторами рецепторов эндотелина в комбинации с цитотоксическим химиотерапевтическим средством
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
PH12014501440A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
PH12019550217A1 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
MX2010001813A (es) Metodos y composiciones para el tratamiento de canceres.
GB201014391D0 (en) Drug composition and its use in therapy
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
CL2013000434A1 (es) Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia.
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
TR201309037A2 (tr) Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
EP2578588A4 (en) NEW DERIVATIVES OF 1, 4 -DIAZEPINES, PDE-5 INHIBITORS
MX2016010912A (es) Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.